1099-1573/asset/PTR_left.gif?v=1&s=61679c959d6ba2d597f752341613b4d11f86e770)
1099-1573/asset/PTR_right.gif?v=1&s=9ab10d74d00053b89129ee4003616901d34ded47)
Short Communication
Regression of cardiac hypertrophy in hypertensive patients—comparison of Abana with propranolol
Article first published online: 4 DEC 1998
DOI: 10.1002/(SICI)1099-1573(199705)11:3<257::AID-PTR79>3.0.CO;2-U
Copyright © 1997 John Wiley & Sons, Ltd.
1099-1573/asset/cover.gif?v=1&s=6a64569c4c1b0de9f4868274faed96fd9265b457 "Phytotherapy Research")
Additional Information
How to Cite
Yegnanarayan, R., Sangle, S. A., Sirsikar, S. S. and Mitra, D. K. (1997), Regression of cardiac hypertrophy in hypertensive patients—comparison of Abana with propranolol. Phytotherapy Research, 11: 257–259. doi: 10.1002/(SICI)1099-1573(199705)11:3<257::AID-PTR79>3.0.CO;2-U
Publication History
- Issue published online: 4 DEC 1998
- Article first published online: 4 DEC 1998
- Manuscript Accepted: 22 SEP 1996
Funded by
- Himalaya Drug Co.
- Abstract
- References
- Cited By
Keywords:
- Abana, propranolol;
- hypertension;
- echocardiography
Abstract
The effect of Abana and propranolol on left ventricular hypertrophy in hypertensive individuals was studied by echocardiography. The study showed an improvement in cardiac function as indicated by an increase in ejection fraction and fractional shortening in both the Abana- and propranolol-treated groups.
A decrease in cardiac mass with propranolol was seen at 12 weeks and was maintained up to 36 weeks. With Abana the reduction in mass was seen from 18 weeks onwards and lasted up to 42 weeks.
In five patients on Abana and two on propranolol, the trial was continued for a further period of 84 weeks, but the effects seen at 84 weeks were not significantly different from these at 60 weeks. © 1997 John Wiley & Sons, Ltd.